
Tatiana Prowell: We are not just here to prevent cancer from progressing. We are here to relieve human suffering, whether it’s suffering from cancer or from the side effects of our treatment.
Tatiana Prowell shared on Twitter/X:
“We are not just here to prevent cancer from progressing. We are here to relieve human suffering, whether it’s suffering from cancer or from the side effects of our treatment. It’s easy to lock onto the tumor as the target our efforts. People with cancer deserve better.”
Source: Tatiana Prowell/Twitter
Tatiana M. Prowell is an Associate Professor of Oncology in the Division of Women’s Malignancies at the Johns Hopkins Kimmel Comprehensive Cancer Center and Breast Cancer Scientific Liaison to the U.S. Food and Drug Administration. She was the principal architect of FDA’s policy on accelerated approval using pathological complete response as a novel regulatory endpoint in the neoadjuvant high-risk breast cancer setting, and a member of the Biden Cancer Moonshot Blue Ribbon Panel Cancer Immunology Working Group. A frequent public speaker, she is a three-time recipient of FDA’s Excellence in Communication Award. She is a past Giants of Cancer Care Award finalist, the recipient of the 2019 John and Samuel Bard Medal in Science or Medicine, and the recipient of a 2020 Webby Special Achievement Award for her effective use of social media during the pandemic. A passionate medical educator and mentor, she was Chair of the 2020 ASCO Annual Meeting Education Committee.
-
Dec 10, 2023, 17:20 | BlogDaniel Blanco: Day 1 of the 2023 St. Jude Global Alliance Convening
-
Dec 10, 2023, 16:59 | InsightYüksel Ürün: MFS continues to be a reliable predictor for overall survival
-
Dec 10, 2023, 18:12The Cancer Research Interns (CRI) Summer Program is now accepting applications! - Train at NCI
-
Dec 10, 2023, 18:08Apply for the Basic Research in Cancer Health Disparities Program - NCI Center to Reduce Cancer Health Disparities (CRCHD)
-
Dec 10, 2023, 18:01Giselle Sholler: Our research that led to the FDA-Oncologic Drugs Advisory Committee 70% approval for moving Difluoromethylornithine forward
-
Dec 10, 2023, 16:59Yüksel Ürün: MFS continues to be a reliable predictor for overall survival
-
Dec 10, 2023, 12:03Eleonora Teplinsky: The POSITIVE Trial SABCS23 updates are so important to help with oncofertility counseling
-
Dec 10, 2023, 16:53Matteo Lambertini: December 7, 2023 …a day to remember
-
Dec 8, 2023, 16:33Big thank you to Dr. Rucha Kiran Patil for sharing their experiences and learnings on writing abstracts and poster presentations - Novo Nordisk Haemophilia Foundation
-
Dec 6, 2023, 14:57Tracy Gosselin: Jennifer Petruno Receives DAISY Award for Extraordinary Nurses
-
Dec 3, 2023, 16:34Tedros Adhanom Ghebreyesus: Grateful to Namibia’s Prime Minister Saara Kuugongelwa-Amadhila for her commitment to health
-
Dec 2, 2023, 18:08100 Influential Celebrities in Oncology: The 2023 Edition – Part 5
-
Dec 10, 2023, 05:08Global Summit on War and Cancer: Agenda
-
Dec 4, 2023, 16:26SIOP 2023 by Numbers! - International Society of Paediatric Oncology
-
Dec 2, 2023, 16:43In our recent survey, nearly 1,700 ASCO members shared feedback on the ABIM MOC requirements - ASCO
-
Nov 28, 2023, 17:34The International Association of Cancer Registries annual conference - IARC
-
Nov 26, 2023, 18:05Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
Dec 10, 2023, 17:39Dr. Salami is the winner of the American Urological Association’s prestigious Gold Cystoscope Award - YUO
-
Dec 10, 2023, 17:26Mark Awad was honored by GO2 for Lung Cancer at the 18th Annual Simply the Best Gala - Dana-Farber Cancer Institute
-
Dec 9, 2023, 17:00Wafik S. El-Deiry: Honored to share the news of my election as the Chair of the WIN Consortium in Personalized Cancer Medicine
-
Dec 8, 2023, 17:54Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
-
Dec 8, 2023, 17:35Timothy M. Pawlik: Excited to announce Samilia Obeng-Gyasi as THE inaugural Endowed Surgical Professor in Health Equity